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Phe Gender-Specific Impact of Diabetes and Myocardial
nfarction at Baseline and During Follow-Up on
ortality From All Causes and Coronary Heart Disease
ang Hu, MD, PHD,*† Pekka Jousilahti, MD, PHD,*† Qing Qiao, MD, PHD,*† Markku Peltonen, PHD,*†
huichi Katoh, MD, PHD,*‡ Jaakko Tuomilehto, MD, PHD*†
elsinki, Finland; and Tokyo, Japan
OBJECTIVES The goal of this study is to compare the magnitude of diabetes and myocardial infarction (MI)
at baseline and during follow-up on cause-specific and all-cause mortality.
BACKGROUND History of both MI and diabetes are strong predictors of coronary heart disease (CHD) death.
However, gender-specific data on the joint effect of diabetes and MI, and particularly on the
effect of incident diabetes and MI developed during the follow-up, on CHD mortality are
scarce.
METHODS The baseline cohort study included 2,416 patients with prior diabetes or MI at baseline; the
follow-up cohort study included 4,315 patients with incident diabetes or MI diagnosed
during the follow-up.
RESULTS In the baseline cohort study, men with prior MI had a 20% to 80% increased risk of CHD
or total mortality, but women with prior MI had a 43% to 45% decreased risk of CHD or
total mortality in comparison with men and women with prior diabetes. In the follow-up
cohort study, men and women with incident MI had a higher risk of CHD mortality (hazard
ratio [HR] 2.15 in men and 1.65 in women), and an almost similar risk of total mortality (HR
0.95 in men and 1.02 in women) in comparison with men and women with incident diabetes.
CONCLUSIONS In men, MI at baseline or during follow-up confers a greater risk on CHD mortality than
diabetes does. In women, prior MI at baseline confers a lower risk on CHD mortality than
prior diabetes does, but incident MI during follow-up confers a greater risk than incident
diabetes does. In both men and women, total mortality is similar for incident MI and
diabetes. (J Am Coll Cardiol 2005;45:1413–8) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.039Cardiology Foundation
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(he number of diabetic patients in the world has been
stimated to at least double during the next 30 years (1).
ardiovascular disease (CVD) accounts for more than 75%
f total mortality among patients with type 2 diabetes (2).
pidemiological studies have indicated that patients with
ype 2 diabetes have a two to four times greater risk of CVD
ortality than those without diabetes. In recent years,
everal studies compared the magnitude of the risk of
istory of type 2 diabetes and myocardial infarction (MI) on
ubsequent coronary heart disease (CHD) or CVD mortal-
ty (3–10). A Finnish prospective study found that the risk
f CHD death among diabetic subjects without prior MI
as similar to nondiabetic subjects with prior MI (3), but
his finding has been challenged by several later studies
5–10). These observational studies usually have a single
aseline measurement (3–10). Only one study has presented
he data on the exposure status changes during the follow-
p, but it adjusted for age only, not taking into account
ther CVD risk factors (6). Thus far no study has compared
he impact of diabetes and MI at baseline and during
From the *Department of Epidemiology and Health Promotion, National Public
ealth Institute, Helsinki, Finland; †Department of Public Health, University of
elsinki, Helsinki, Finland; and ‡Department of Internal Medicine, Jikei University
chool of Medicine, Tokyo, Japan. This study was supported by grants from the
innish Academy (grants 46558, 53585, 204274, and 205657). Dr. Katoh’s work is
upported by a grant from Uehara Memorial Foundation in Japan.f
Manuscript received September 28, 2004; revised manuscript received January 13,
005, accepted January 17, 2005.ollow-up on CHD mortality with adjustment for major
VD risk factors. The aim of this study is to compare the
ndependent and joint effects of diabetes and MI at baseline
nd during follow-up on CHD, CVD, non-CVD, and total
ortality.
ETHODS
ubjects. Six independent population surveys were carried
ut in five geographic areas of Finland in 1972, 1977, 1982,
987, 1992, and 1997 (11). In 1972 and 1977, a randomly
elected sample making up 6.6% of the population born
etween 1913 and 1947 was drawn. Since 1982, the sample
as stratified by area, gender, and 10-year age group
ccording to the World Health Organization MONICA
MONItoring trends and determinants of CArdiovascular
isease) protocol (12). In six surveys, the subjects included
ere 25 to 64 years of age, and, in the 1997 survey, subjects
ge 65 to 74 years were also included. Subjects who
articipated in more than one survey were included in the
rst survey cohort only. The total sample size of the six
urveys was 53,166. The participation rate varied by year
rom 74% to 88% (11). We carried out two studies in the
resent analyses: the baseline cohort study included patients
ith prior diabetes or MI at baseline (n  2,416), and the
ollow-up cohort study included patients with incident
diagnosed after the baseline survey) diabetes or MI during
ollow-up (n  4,315). These surveys were conducted
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Diabetes, MI, and Mortality May 3, 2005:1413–8ccording to the ethical rules of the National Public Health
nstitute, and the investigations were carried out in accor-
ance with the Declaration of Helsinki.
easurements. A self-administered questionnaire was
ailed to the participants. It included questions about
moking and medical history. Based on the responses, the
articipants were classified as never, previous, and current
mokers. At the study site, specially trained research nurses
easured blood pressure, height, and weight using a stan-
ardized protocol (12). Blood pressure was measured after
min of rest using a standard mercury manometer. Height
as measured without shoes. Weight was measured with
ight clothing. Body mass index (BMI) was calculated as
eight in kilograms divided by the square of the height in
eters. After blood pressure measurement, a venous blood
pecimen was drawn. Total cholesterol concentration was
etermined by using the Lieberman Burchard method in
972 and 1977, and an enzymatic method (CHOD-PAP,
oehringer Mannheim, Mannheim, Germany) since 1982.
ecause the enzymatic method gave 2.4% lower values than
he Lieberman Burchard method, 1972 and 1977 values are
orrected by this percentage. All samples were analyzed in
he same laboratory at the National Public Health Institute.
ssessment of diabetes and MI at baseline and during
ollow-up. Assessment of diabetes and MI status was based
n self-reporting and on the data of two nationwide
egisters. The National Hospital Discharge Register data
ncluded hospital discharge diagnosis from 1968 through
he end of 2000. Validity of the data has been assessed and
ound to be generally good (13). Data on diabetes medica-
ion were ascertained from the National Social Insurance
nstitution’s Register on special reimbursement for antidia-
etic drugs from 1964 through the end of 2000. Antidia-
etic drugs prescribed by a physician are free of charge in
inland and are subject to approval of a physician who
eviews each case history. The physician confirms the diag-
osis of diabetes by applying the World Health Organization
riteria (14,15). All patients receiving free medication (either
ral antidiabetic agents or insulin) are entered into a register
aintained by the Social Insurance Institution.
Subjects who reported having diabetes on the question-
aire, or who had had a hospital discharge diagnosis of
iabetes, or the approval for free-of-charge medication for
iabetes before the baseline survey, were classified as having
rior diabetes at baseline. The subjects with prior MI at
Abbreviations and Acronyms
BMI  body mass index
CHD  coronary heart disease
CI  confidence interval
CVD  cardiovascular disease
HR  hazard ratio
ICD  International Classification of Diseases
MI  myocardial infarctionaseline were those who reported having MI on the ques- 1ionnaire, or had had a hospital discharge diagnosis of MI
efore the baseline survey.
Subjects who had the first hospital discharge diagnosis
ith diabetes, or the approval for free-of-charge medication
or diabetes after the baseline survey were classified as
aving incident diabetes during the follow-up. Subjects with
ncident MI during the follow-up comprised those who had
hospital discharge with a diagnosis of MI after the baseline
urvey. Age and person-years of follow-up were calculated
t their date of new diagnosis of diabetes or MI during
ollow-up. The patients who died within 28 days from the
iagnosis date of incident diabetes and MI during follow-up
ere excluded from the analysis, thus eliminating the deaths
irectly due to MI.
rospective follow-up. The study cohorts were followed
ntil the end of 2001 through computerized register linkage
sing the personal identification number assigned for every
esident in Finland. Mortality data were obtained from
tatistics Finland. The International Classification of Dis-
ases (ICD), Eighth, Ninth, and Tenth Revisions, were
sed for coding the causes of death; ICD codes 390-459 and
00-I99 were classified as CVD deaths, 410-414 and I20-
25 as CHD deaths.
tatistics. SPSS for Windows 11.5 was used for statistical
nalysis. The gender-specific CHD, CVD, non-CVD, and
otal mortality rates were calculated by 10-year age intervals
nd standardized for age by the direct method using a Euro-
ean standard population age 25 to 74 years (16) for each of
hree groups: diabetes, MI, and both. The Cox proportional
azard models (17) were used to estimate the hazard ratios
HRs) of cause-specific and all-cause mortality associated with
iabetes and MI status. The reference group was the subjects
ith diabetes at baseline or during follow-up. The analyses
ere first carried out adjusting for age and study year only, and
hen adjusting further for BMI, systolic blood pressure, total
holesterol, and smoking at baseline. The likelihood ratio test
or interaction was carried out to test whether the effect of
isease status on mortality was the same in men and women. A
value of 0.05 was considered to be statistically significant,
nd all p values were two-sided.
ESULTS
aseline cohort study. Baseline characteristics and
ultivariate-adjusted (age, study year, BMI, systolic blood
ressure, cholesterol, and smoking) HRs of mortality ac-
ording to the prior history of diabetes and MI at baseline
re presented in Table 1. During a mean follow-up period of
2 years, we identified 1,119 deaths from all causes among
,416 patients with prior diabetes and MI at baseline, of
hich 591 deaths were coded as CHD, 781 deaths as CVD,
nd 338 deaths as non-CVD. Compared with men with
rior diabetes at baseline, men with prior MI had a higher
isk of death from CHD (HR, 1.78; 95% confidence
nterval [CI], 1.39 to 2.27), from CVD (HR, 1.43; 95% CI,
.16 to 1.77), and from all causes (HR, 1.22; 95% CI, 1.03
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May 3, 2005:1413–8 Diabetes, MI, and Mortalityo 1.44). In women, however, those with prior MI had a
ower risk of death from CHD (HR, 0.57; 95% CI, 0.39 to
.82), from CVD (HR, 0.63; 95% CI, 0.47 to 0.84), from
on-CVD (HR, 0.40; 95% CI, 0.26 to 0.62), and from all
auses (HR, 0.55; 95% CI, 0.43 to 0.70) compared with
omen with prior diabetes at baseline. These gender
ifferences in HRs were statistically significant for CHD
ortality (chi-square  23.58, 1 df, p  0.001), CVD
ortality (chi-square  21.21, 1 df, p  0.001), non-
VD mortality (chi-square 8.24, 1 df, p 0.005), and total
ortality (chi-square  29.5, 1 df, p  0.001). Men and
omen with both prior diabetes and MI at baseline showed
he highest risks of death from CHD, CVD, and all causes.
atients with incident diabetes and MI during follow-
p. For this cohort with a mean follow-up period of 7.7 years,
e identified 1,578 deaths from all causes among 4,315
atients with incident diabetes or MI, of which 825 deaths
ere coded as CHD, 1,094 deaths as CVD, and 484 deaths as
on-CVD (Table 2). Compared with men and women with
ncident diabetes, men and women with incident MI had
able 1. Baseline Characteristics* and HR of Coronary Heart Di
ccording to the History of Diabetes and MI at Baseline
Prior
Diabetes Prior
of subjects 496 98
ge at baseline (yrs) 53.0 5
ody mass index (kg/m2) 28.2 2
iastolic blood pressure (mm Hg) 90 8
ystolic blood pressure (mm Hg) 151 14
erum cholesterol (mmol/l) 6.1
moking (%)
Never 31.5 1
Past 33.7 4
Current 34.9 3
erson-yrs 6,070 10,52
oronary heart disease mortality
# of deaths 85 32
Mortality rate/10,000 person-yrs† 117.3 20
Age and study year adjustment HR (95% CI) 1.00 1.87 (1.47
Multivariate adjustment HR (95% CI)‡ 1.00 1.78 (1.39
ardiovascular mortality
# of deaths 127 37
Mortality rate/10,000 person-yrs† 173.6 24
Age and study year adjustment HR (95% CI) 1.00 1.46 (1.19
Multivariate adjustment HR (95% CI)‡ 1.00 1.43 (1.16
oncardiovascular mortality
# of deaths 80 13
Mortality rate/10,000 person-yrs† 127.4 8
Age and study year adjustment HR (95% CI) 1.00 0.88 (0.66
Multivariate adjustment HR (95% CI)‡ 1.00 0.88 (0.66
otal mortality
# of deaths 207 51
Mortality rate/10,000 person-yrs† 301.0 33
Age and study year adjustment HR (95% CI) 1.00 1.24 (1.05
Multivariate adjustment HR (95% CI)‡ 1.00 1.22 (1.03
Baseline characteristics represent mean or percentage; †age-standardized mortality ra
or age at baseline, study year, body mass index, systolic blood pressure, total choles
CI  confidence interval; HR  hazard ratio; MI  myocardial infarction.igher multivariate-adjusted HRs of CHD mortality (2.15; w5% CI, 1.70 to 2.73 in men; 1.65; 95% CI, 1.27 to 2.14 in
omen) and CVD mortality (1.41; 95% CI, 1.16 to 1.71 in
en; 1.22; 95% CI, 0.98 to 1.53 in women), lower HRs of
on-CVDmortality (0.42; 95% CI, 0.33 to 0.55 in men; 0.66;
5% CI, 0.46 to 0.93 in women), and almost similar HRs of
otal mortality (0.95; 95% CI, 0.82 to 1.11 in men; 1.02; 95%
I, 0.84 to 1.23 in women). There was no gender difference in
HD, CVD, non-CVD, and all-cause mortality (chi-square
1.30, 0.59, 2.32, and 0.23, respectively, 1 df, all p  0.1).
en and women with both incident diabetes and MI showed
he highest risks of CHD and total mortality.
The cumulative survival probability curves further illustrate
he different patterns in CHD mortality associated with dia-
etes and MI status at baseline and during the follow-up (Fig.
). Men with prior MI at baseline had a worse survival than
en with prior diabetes did. However, the survival curves were
eversed in women with prior diabetes at baseline being
ssociated with a worse survival than was prior MI. When the
isease status during follow-up was considered, men and
omen with incident MI had a worse survival in comparison
, Cardiovascular, Noncardiovascular, and Total Mortality
Women
Prior Diabetes
and MI
Prior
Diabetes Prior MI
Prior Diabetes
and MI
99 466 326 47
58.7 52.4 58.3 60.1
29.3 29.7 29.5 31.1
85 88 90 90
150 152 153 161
6.3 6.3 6.8 6.7
19.2 79.2 78.5 78.7
48.5 7.3 10.4 8.5
32.3 13.5 11.1 12.8
859 6,376 4,731 479
42 74 53 17
365.9 88.7 55.6 226.3
) 2.93 (2.01–4.26) 1.00 0.58 (0.40–0.83) 2.73 (1.58–4.71)
) 2.97 (2.03–4.34) 1.00 0.57 (0.39–0.82) 2.26 (1.29–3.97)
56 120 86 21
503.0 148.8 110.4 272.8
) 2.65 (1.92–3.65) 1.00 0.61 (0.46–0.81) 2.09 (1.30–3.36)
) 2.76 (2.00–3.81) 1.00 0.63 (0.47–0.84) 1.84 (1.13–3.00)
11 72 31 5
95.9 93.0 43.2 58.1
) 0.86 (0.46–1.63) 1.00 0.40 (0.26–0.62) 0.78 (0.31–1.97)
) 0.95 (0.50–1.80) 1.00 0.40 (0.26–0.62) 0.70 (0.28–1.78)
67 192 117 26
598.9 241.8 153.6 330.9
) 1.97 (1.49–2.61) 1.00 0.54 (0.42–0.68) 1.58 (1.04–2.40)
) 2.08 (1.57–2.76) 1.00 0.55 (0.43–0.70) 1.41 (0.92–2.16)
calculated using a European standard population by 10-year age intervals; ‡adjusted
nd smoking.sease
Men
MI
2
6.9
7.7
9
7
6.5
6.8
3.6
9.6
9
0
8.5
–2.38
–2.27
1
4.4
–1.79
–1.77
9
8.1
–1.16
–1.17
0
2.4
–1.46
–1.44
te wasith subjects with incident diabetes.
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en with prior history of MI at baseline were at higher risk
f CHD and total mortality than men with history of
iabetes at baseline; in women, the magnitude of the
ssociation was reversed, and prior diabetes at baseline was
ssociated with a greater risk of CHD and total mortality
han prior MI at baseline. When the disease status during
ollow-up was considered, men and women with incident
I had a higher risk of CHD mortality, and almost similar
isk of total mortality in comparison with subjects with
ncident diabetes. Men and women with both diabetes and
I at baseline or during follow-up showed the highest risk.
Using the same design as our baseline cohort study, several
revious studies compared the magnitude of the risk of history
f type 2 diabetes and MI on subsequent CHD or CVD
able 2. Baseline Characteristics* and HR of Coronary Heart Di
ccording to Incident Diabetes and MI During Follow-Up
Men
Incident
Diabetes Incident M
of subjects 981 1,308
ge at diagnosed date (yrs) 60.1 59.5
ody mass index (kg/m2) 29.2 26.5
iastolic blood pressure (mm Hg) 94 92
ystolic blood pressure (mm Hg) 150 148
erum cholesterol (mmol/l) 6.5 7.0
moking (%)
Never 25.8 23.9
Past 26.9 22.3
Current 47.3 53.7
erson-yrs 6,607 11,215
oronary heart disease mortality
# of deaths 102 365
Mortality rate/10,000 person-yrs† 150.4 301.7
Age and study year adjustment HR
(95% CI)
1.00 2.04 (1.64–2.5
Multivariate adjustment HR (95% CI)‡ 1.00 2.15 (1.70–2.7
ardiovascular mortality
# of deaths 178 418
Mortality rate/10,000 person-yrs† 273.0 346.7
Age and study year adjustment HR
(95% CI)
1.00 1.33 (1.11–1.5
Multivariate adjustment HR (95% CI)‡ 1.00 1.41 (1.16–1.7
oncardiovascular mortality
# of deaths 143 126
Mortality rate/10,000 person-yrs† 226.2 111.5
Age and study year adjustment HR
(95% CI)
1.00 0.49 (0.38–0.6
Multivariate adjustment HR (95% CI)‡ 1.00 0.42 (0.33–0.5
otal mortality
# of deaths 321 544
Mortality rate/10,000 person-yrs† 499.2 458.2
Age and study year adjustment HR
(95% CI)
1.00 0.95 (0.83–1.1
Multivariate adjustment HR (95% CI)‡ 1.00 0.95 (0.82–1.1
Baseline characteristics represent mean or percentage; †age-standardized mortality ra
or age at diagnosed date, study year, body mass index, systolic blood pressure, total
CI  confidence interval; HR  hazard ratio; MI  myocardial infarction.ortality (3–10), but the results were inconsistent. The anal- hses from another Finnish cohort study (3) and from the
urses’ Health study (4) found that the risk of CHDmortality
mong subjects with a history of diabetes without priorMI was
imilar to that in nondiabetic subjects with prior MI. The
ealth Professionals Follow-up study (5), a Scottish
opulation-based study (6), the Atherosclerosis Risk in Com-
unities study (9), and the Multiple Risk Factor Intervention
rial (10) consistently reported that the magnitudes of CHD
nd CVD mortality were weaker for prior diabetes at baseline
han that associated with priorMI. Only two studies compared
HD mortality associated with prior diabetes and established
I in men and women separately (7,8). In the Hoorn study,
omen with prior diabetes at baseline had a risk of CVD
vents that was similar to that of nondiabetic women with prior
VD, whereas nondiabetic men with prior CVD conferred a
, Cardiovascular, Noncardiovascular, and Total Mortality
Women
Incident
Diabetes and
MI
Incident
Diabetes Incident MI
Incident
Diabetes and
MI
171 1,155 566 134
58.6 64.2 66.1 63.3
29.3 31.0 27.5 31.7
96 94 92 97
154 157 155 165
6.9 6.7 7.2 6.8
22.8 84.2 80.6 85.1
28.7 3.0 3.4 2.2
48.5 12.7 16.1 12.7
971 9,304 4,646 662
47 146 126 39
506.9 123.7 190.5 496.7
3.42 (2.42–4.84) 1.00 1.57 (1.23–1.99) 4.18 (2.92–5.98)
3.24 (2.28–4.60) 1.00 1.65 (1.27–2.14) 3.91 (2.73–5.60)
57 241 147 53
606.0 206.6 222.3 660.4
2.42 (1.79–3.27) 1.00 1.10 (0.90–1.36) 3.43 (2.53–4.63)
2.32 (1.71–3.14) 1.00 1.22 (0.98–1.53) 3.22 (2.38–4.36)
22 131 49 13
205.2 119.3 105.1 185.3
1.22 (0.78–1.93) 1.00 0.65 (0.47–0.91) 1.57 (0.88–2.79)
1.30 (0.83–2.05) 1.00 0.66 (0.46–0.93) 1.61 (0.90–2.87)
79 372 196 66
811.2 325.9 327.4 845.7
1.89 (1.48–2.42) 1.00 0.94 (0.79–1.12) 2.78 (2.13–3.62)
1.87 (1.46–2.40) 1.00 1.02 (0.84–1.23) 2.67 (2.05–3.48)
calculated using a European standard population by 10-year age intervals; ‡adjusted
terol, and smoking.sease
I
5)
3)
9)
1)
2)
5)
0)
1)
te wasigher risk of CVD events compared with men with prior
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May 3, 2005:1413–8 Diabetes, MI, and Mortalityiabetes and without prior CVD (8). The analysis from the
ramingham study indicated that, in men, prior CHD at
aseline signifies a higher risk for CHD mortality than does
rior diabetes; however, this was reversed in women, with prior
iabetes being associated with greater risk for CHD mortality
7), which is consistent with our baseline cohort study.
Only data from a Scottish population-based study compared
he magnitude of the incident diabetes and MI during the
ollow-up on the risk of CVD mortality (6), which used the
ame design as our follow-up cohort study. The present study
howed a higher risk for CHD mortality, and almost similar
isk for total mortality in patients with incident MI compared
ith patients with incident diabetes. The analysis from the
cottish population-based study found that patients with
ncident MI had a higher risk of CVD and total mortality than
atients with incident diabetes had, but this study did not
djust for other CVD risk factors besides age and gender (6).
In the present study, women with prior MI at baseline
ad a markedly lower risk of CHD and total mortality
ompared with women with prior diabetes at baseline,
hereas, in the follow-up study, this association was re-
ersed, and women with incident MI had a higher risk
ompared with women with incident diabetes. The magni-
ude of the effect of diabetes and MI on CHD risk most
robably depends on the duration of the disease, and this
igure 1. The multivariate-adjusted cumulative survival curves of coronary
A  men; B  women) and during follow-up (C  men; D women
holesterol, and smoking. DM  diabetes.ime factor may operate differently for diabetes than for MI. imong patients who have survived an acute MI, the risk of
ubsequent CHD event is highest right after the attack, and
he risk stabilizes over time, whereas, among diabetic
ubjects, the risk increases with the duration of the disease
10). Most previous studies, similar to our baseline cohort
nalyses, have not paid attention to the time of the MI
vent, or the duration of diabetes, in their data analyses.
When comparing absolute mortality, the largest gender
ifferential on CHD, CVD, and total mortality (adjusted
or age) appeared in patients with MI and became smaller
nd almost nonexistent in diabetic patients. The findings
rom our study further support the hypothesis that the
resence of diabetes reduces the usual female advantage
egarding CHD (18,19). More aggressive management of
iabetes to prevent CVD may be needed, particularly in
omen. The United Kingdom Prospective Diabetes study
UKPDS) demonstrated the importance of maintaining
ood glycemic control to prevent the development and
rogression of complications among patients with type 2
iabetes (20). Clinical trials have also shown that pharma-
ological treatment of hypertension (21–24) and cholesterol
eduction with a statin therapy (25–27) are efficient ways to
revent CHD in diabetic patients. While a more efficient
ontrol of hyperglycemia and other CVD risk factors are
tality associated with diabetes and myocardial infarction (MI) at baseline
usted for age, study year, body mass index, systolic blood pressure, totalmormportant in all diabetic patients, it is possible that women
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Diabetes, MI, and Mortality May 3, 2005:1413–8ith diabetes may particularly benefit from more intensive
ntervention strategies to reduce the risk of CVD.
There are several strengths and limitations in our study.
e have a unique possibility to stratify for both baseline and
ollow-up status of diabetes and MI. The number of
atients is large and from a homogeneous population. The
ean follow-up was sufficiently long, during which a large
umber of cardiovascular end point events were ascertained.
e also excluded subjects with type 1 diabetes from the
nalysis. Finally, due to computerized data linkage of
ational mortality data, the end point data collection was
ractically complete. A limitation of our study was that we
ould not have the data on drug treatment for diabetes, MI,
nd other chronic diseases.
In conclusion, we compared the independent effects of
iabetes and MI at baseline and during the follow-up on the
isk of death. In men, MI at baseline or during the follow-up
s associated with a greater risk on CHD mortality than seen
ith diabetes. In women, priorMI at baseline increases the risk
f CHD mortality less than prior diabetes does, but incident
I during follow-up has a greater risk than incident diabetes.
n both men and women, total mortality is similar between
ncident MI and diabetes during follow-up. The results of our
tudy have important implications for clinical practice: first, we
eed to consider carefully the treatment strategies on individual
isease status, particularly type 2 diabetes in women, for future
VD risk. Furthermore, in order to reduce CVD mortality,
ore active management and prevention of diabetes are
eeded.
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